Full Title
A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung CancerPurpose
This study is assessing an immunotherapy called tislelizumab alone and with other medications in people with advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that is inoperable (cannot be taken out with surgery).
People whose tumors contain high levels of a protein called PD-L1 will be randomly assigned to get one of these treatments:
- Tislelizumab alone
- Tislelizumab with BGB-A445, LBL-007, or another investigational immunotherapy (to be determined)
People whose tumors have low PD-L1 levels will be randomly assigned to one of these treatments:
- Tislelizumab with standard chemotherapy (carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed)
- Tislelizumab with standard chemotherapy (carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed) plus BGB-A445 or LBL-007
- Tislelizumab with standard chemotherapy (carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed) plus another investigational immunotherapy drug (to be determined)
Who Can Join
To join this study, there are a few conditions. You must:
- Have NSCLC that is inoperable and has spread beyond its original location.
- Not have had treatment for advanced lung cancer. Any prior treatment must have finished at least 6 months before you get the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call the office of Dr. Jamie Chaft at 646-608-3761 or Dr. Alissa Cooper at 646-608-4322.